Egetis Therapeutics AB (0ABW) Share Forecast & Price Target
0ABW Analyst Ratings
0ABW Stock 12 Month Forecast
Average Price Target
SEK 33.00▲(211.32% Upside)Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Kristen Kluska | Cantor Fitzgerald | SEK 23→SEK 33 | buy | 211.32%Upside | Reiterated | 09/29/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Kristen Kluska | 09/29/26 | SEK 23→SEK 33 | buy | 211.32%Upside | Reiterated | Cantor Fitzgerald |
Best Analysts Covering Egetis Therapeutics AB
Copying Kristen Kluska's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +36.70% per trade.
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +60.90% per trade.
Copying Kristen Kluska's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +60.90% per trade.
0ABW Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 1 | 1 | 1 | 1 |
In the current month, 0ABW has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0ABW average Analyst price target in the past 3 months is 33.00.
0ABW Financial Forecast
0ABW Earnings Forecast
Next quarter’s earnings estimate for 0ABW is -SEK 0.20 with a range of -SEK 0.21 to -SEK 0.18. The previous quarter’s EPS was -SEK 0.25. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
0ABW Sales Forecast
Next quarter’s sales forecast for 0ABW is SEK 24.88M with a range of SEK 16.52M to SEK 35.10M. The previous quarter’s sales results were SEK 17.40M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.